Executive Team
Epica International, Inc.
E P i C A
LEADERS
The future we see is non-contact imaging and robotic assistance.
Epica International, Inc. provides more precise procedures and better
quality imaging for safer operations and improved outcomes.
Meet The Team
Thomas Grossman
Chairman, Board of Directors
Mr. Grossman presently runs Union Avenue Advisors LP, a company he founded in 2009, where he builds customized portfolios for separately managed accounts in the international markets. Prior to starting Union Avenue Advisors, Mr. Grossman was a portfolio manager at Ospraie Management, LLC from 2007 to 2008. He also established Aeneas Capital Management in 2000 and ran the business through 2008. Mr. Grossman’s extensive financial background includes positions as director of SAC International Equities LLC from 1997-2000, head of international trading for Kingdom Capital Management LLC from 1994-1997, international sales and trading desk at Goldman Sachs & Co from 1992-1994, analyst at Bridge Trading Co. from 1990-1992, and trader in equity options at Shearson Lehman Hutton from 1988-1990. Mr. Grossman graduated cum laude from Lehigh University, where he received a BS in finance.
Dr. Randy Axelrod, M.D.
CEO of Epica International, Director
Dr. Axelrod is a Seasoned Physician executive and healthcare thought leader with more than 30 years of cumulative experience, accountability and achievements in for profit, public, and not-for-profit healthcare organizations with responsibility in all areas of healthcare and financial structures, initiating, managing and operating multibillion dollar businesses and developing and executing comprehensive strategic plans resulting in improved financial returns, clinician engagement, clinical improvements and healthier communities.
Dr. Axelrod served as the Executive Vice President and Chief Clinical Officer for Providence Health & Services, organizing system wide quality and safety, clinical programs, clinical innovation, research evaluation and key supply chain and capital purchase strategies. Previously he served as SVP for Healthcare Management at WellPoint, the VP and Executive Medical Director at Sentara Healthcare and the President of HealthSpring Medical Group. Dr. Axelrod’s work on the use of artificial intelligence in health care resulted in internationally accepted publications and several national awards. Recently Dr. Axelrod and the POWERDOT team won first-place in the Heritage Health Plan predictive modeling contest at the first and second milestones and final competition – a contest predicting readmissions. He has also received the Virginia Public Health Association Recognition Award.
Dr. Axelrod earned his MD at The University of Cincinnati Medical School and was a practicing pediatric physician and surgeon.
Dr. Damiano Fortuna
President of Epica International, CEO & President of Imaginalis, Director
Dr. Fortuna is president of Epical International as well as CEO and president of Imaginalis S.r.l, the manufacturer of Epica’s HDCT products. Prior to Epica, Dr. Fortuna served as the executive director of the PhotoBioLab research unit of El.En. s.p.a., the market leader in laser research and manufacturing for medical and industrial applications. Dr. Fortuna spent seventeen years in veterinary practice and twelve years in basic and applied veterinary medical research of laser surgery and therapy with El.En. s.p.a. He received his degree in veterinary medicine from University of Pisa and completed postdoctoral training through various universities in Europe, where he focused on Italian veterinary medicine, food hygiene, public health, and innovative microscopy for biotechnology.
Dr. Renzo Valleggi
Chief Technology Officer of
Epica International, Director
Dr. Valleggi is a founder, board chair, and chief executive officer of Gruppo Scienzia Machinale S.r.l. An accomplished mechanical engineer, he has worked in the research, development, and robotics department of Scienzia Machinale (the first spin-off of the Scuola Superiore Sant’Anna in Pisa) since 1992. Dr. Valleggi spent more than fifteen years developing innovative products for defense, healthcare, and domestic appliances within the industrial automation sectors. Dr. Valleggi is the author of several patents and holds a Ph.D. in the mechanics of materials from the University of Pisa.
Dan McMahon
Senior Vice President of Worldwide
Sales, Epica International
Dan McMahon is Epica's Senior
Vice President of Worldwide Sales covering Epica's human health, animal health and robotics' portfolios. In his extensive 24 year medical device career, Dan has successfully launched 14 human imaging platforms, numerous medical devices and has extensive knowledge of advanced minimally invasive surgery and medical imaging systems. Prior to Epica, Dan held senior sales management and GM positions at Karl Storz and Olympus where he led sales and commercialization and consistently exceeded sales expectations. As the General Manager for KARL STORZ and the West Area Vice President of Sales for Olympus Medical, Mr. McMahon has spent the last 24 years focused on medical imaging. He has collaborated closely with both the R&D and Marketing teams to validate and test new medical device products.
Daniel Naimey
Senior Vice President Business Development, Strategy & Marketing
Daniel Naimey serves as Epica International’s Senior Vice President, Business Development, Market Development and Strategy. Mr. Naimey focuses on development and global expansion of Epica's HDVI CT Imaging Platforms and surgical robotics technologies into the human healthcare market. He also provides marketing and analytical support for the company’s Human CT, Robotics and software ecosystem program development. Mr. Naimey's prior experience includes management positions at Stryker and Covidien, where he led endo-mechanical business development/M&A and held a GM role in the company's global sports medicine business. He was also the business development/M&A lead for the Surgical Solutions' Advanced MIS Group, driving inorganic and new product development and revenue growth from the company's 2007 IPO to its acquisition by Medtronic in 2015. Daniel has an extensive knowledge of advanced minimally invasive surgery, diagnostic and intraoperative imaging and surgical robotics. He facilitated the acquisition of numerous med device companies, robotic surgery assets, and initiated Covidien's move into non-invasive surgery systems for lung cancer diagnostics. He has launched and branded medical devices globally.